Acumen Pharmaceuticals (ABOS) Payables (2020 - 2026)

Acumen Pharmaceuticals' Payables history runs 7 years deep, the most recent figure standing at $15.8 million for Q1 2026.

• In Q1 2026, Payables rose 1394.13% year-over-year to $15.8 million; the TTM figure through Mar 2026 stood at $15.8 million (up 1394.13% YoY), while the FY2025 annual figure was $9.3 million, up 65.0% from the prior year.
• Payables came in at $15.8 million for Q1 2026 at Acumen Pharmaceuticals, up from $9.3 million in the prior quarter.
• In the past five years, Payables ranged from a high of $15.8 million in Q1 2026 to a low of $1.1 million in Q1 2025.
• A 5-year average of $3.9 million and a median of $2.7 million in 2023 frame the typical range for Payables.
• Across the five-year window, Payables tumbled 69.02% in 2023 and surged 1394.13% in 2026, its largest moves.
• Acumen Pharmaceuticals' Payables stood at $1.6 million in 2022, then slipped by 15.91% to $1.4 million in 2023, then surged by 309.57% to $5.6 million in 2024, then jumped by 65.0% to $9.3 million in 2025, then jumped by 69.31% to $15.8 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $15.8 million, $9.3 million, and $4.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison